MacroGenics (MGNX) AI Stock Analysis

• Market Cap: $127.68M
• Dividend Yield: N/A
• Average Volume (3M): 737.18K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.13
• Revenue Growth: 303.47%
• EPS Growth: 73.70%
• Country: US
• Employees: 341
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 63,205,704
• 10 Day Avg. Volume: 928,151
• 30 Day Avg. Volume: 737,182
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.06
• Enterprise Value/Revenue: 0.05
• Enterprise Value/Gross Profit: 0.05
• Enterprise Value/Ebitda: -0.16
• 1Y Price Target: $3.75
• Price Target Upside: 104.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 51 Neutral
• Price Target: $2.00 ▲(9.29% Upside)

MacroGenics' stock score is primarily influenced by its challenging financial performance, with ongoing profitability and cash flow issues. However, technical analysis shows positive momentum, which partially offsets the financial concerns. Valuation remains a significant risk due to negative earnings and lack of dividends.

Positive Factors

Revenue Growth

Positive revenue growth indicates potential market expansion and product adoption, which can enhance long-term business sustainability.

Gross Profit Margin

A high gross profit margin reflects efficient production and cost management, supporting long-term profitability potential.

Cash Generation Ability

Positive cash generation relative to net losses suggests the company can sustain operations and invest in growth despite profitability challenges.

Negative Factors

Profitability Issues

Ongoing profitability challenges could hinder long-term financial health and limit the ability to reinvest in business growth.

Negative Return on Equity

Negative return on equity indicates inefficient use of shareholder capital, potentially impacting investor confidence and future capital raising.

Operating Cash Flow Challenges

Negative operating cash flow suggests difficulties in generating sufficient cash from core operations, which may affect long-term viability.

MacroGenics Business Overview & Revenue Model

Company Description

MacroGenics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company specializes in leveraging its proprietary technology platforms, including antibody-drug conjugates and bispecific antibodies, to create targeted therapies that improve patient outcomes. MacroGenics aims to address significant unmet medical needs through its extensive pipeline of product candidates, which are designed to enhance the efficacy and safety profiles of existing treatments.

How the Company Makes Money

MacroGenics generates revenue primarily through the development and commercialization of its therapeutic products. The company earns money from product sales once its drugs receive regulatory approval and are launched into the market. In addition to direct sales, MacroGenics also benefits from collaborative agreements and partnerships with larger pharmaceutical companies, which can include upfront payments, milestone payments based on the achievement of development goals, and royalties on future product sales. These partnerships allow MacroGenics to leverage the resources and expertise of larger entities while sharing the financial risks associated with drug development. Furthermore, the company may also receive funding through grants or government programs aimed at supporting innovative healthcare solutions.

MacroGenics Financial Statement Overview

Summary

MacroGenics faces significant financial challenges, with profitability and liquidity being major concerns. Despite strong gross profit margins, the company struggles with negative EBIT and net profit margins, indicating ongoing operational challenges.

Income Statement

MacroGenics has shown inconsistent revenue growth, with a significant increase in 2023 but a decline in 2024. The gross profit margin remains strong, but the company struggles with negative EBIT and net profit margins, indicating ongoing operational challenges and profitability issues.

Balance Sheet

The balance sheet reflects moderate stability with a manageable debt-to-equity ratio. However, the declining stockholders' equity and high liabilities suggest potential financial strain. The equity ratio is decreasing, indicating a reliance on debt financing.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, indicating liquidity challenges. The free cash flow to net income ratio is negative, highlighting the company's difficulty in converting earnings into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	152.43M	148.34M	57.19M	151.94M	75.64M	97.76M
Gross Profit	136.84M	136.04M	48.97M	144.56M	72.99M	-95.44M
EBITDA	-47.33M	-57.37M	2.02M	-107.89M	-190.86M	-117.78M
Net Income	-55.81M	-66.97M	-9.06M	-120.02M	-190.86M	-117.78M
Balance Sheet
Total Assets	224.56M	261.65M	298.42M	280.47M	335.25M	378.74M
Cash, Cash Equivalents and Short-Term Investments	154.14M	201.67M	229.81M	154.35M	243.62M	272.53M
Total Debt	37.47M	37.46M	33.97M	34.83M	25.47M	29.25M
Total Liabilities	145.45M	145.60M	145.81M	138.46M	95.63M	82.86M
Stockholders Equity	79.12M	116.06M	152.61M	142.01M	239.62M	295.88M
Cash Flow
Free Cash Flow	-72.40M	-72.08M	-79.97M	-90.58M	-150.03M	-117.80M
Operating Cash Flow	-69.62M	-68.37M	-78.20M	-86.96M	-143.83M	-111.90M
Investing Cash Flow	134.41M	149.30M	-80.08M	70.72M	-36.61M	-7.79M
Financing Cash Flow	430.00K	960.00K	150.36M	1.66M	122.78M	174.34M

MacroGenics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGNX, the sentiment is Positive. The current price of 1.83 is above the 20-day moving average (MA) of 1.74, above the 50-day MA of 1.70, and below the 200-day MA of 1.85, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 54.71 is Neutral, neither overbought nor oversold. The STOCH value of 69.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGNX.

MacroGenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	52 Neutral	$120.50M	―	-25.25%	―	12.13%	-8.23%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MGNX	51 Neutral	$127.68M	―	-69.71%	―	303.47%	73.70%
ANIX	49 Neutral	$132.98M	―	-57.94%	―	―	11.78%
ORMP	47 Neutral	$93.90M	―	-14.57%	―	―	-217.26%
SRZN	43 Neutral	$116.39M	―	-130.27%	―	―	35.81%
ATOS	36 Underperform	$118.84M	-4.07	-41.66%	―	―	-8.91%

MacroGenics Corporate Events

MacroGenics Inc. Reports Q2 2025 Financial Results

MacroGenics Inc., a clinical-stage biopharmaceutical company, specializes in developing innovative antibody-based therapeutics for cancer treatment, leveraging its proprietary antibody technology platforms. In its latest earnings report for the quarter ending June 30, 2025, MacroGenics Inc. reported total revenues of $22.2 million, a significant increase from $10.8 million in the same period last year. This growth was primarily driven by contract manufacturing revenues, which rose to $15.4 million from $2.9 million. However, the company recorded a net loss of $36.3 million, a decrease from the $55.7 million loss in the previous year, reflecting ongoing investments in research and development. Key financial highlights include a decline in cash and cash equivalents to $130.7 million from $182.8 million at the end of 2024, and a liability related to future royalties of $70.3 million following a royalty monetization arrangement. Looking ahead, MacroGenics remains focused on advancing its pipeline of product candidates and leveraging strategic collaborations to support its development efforts. The company anticipates that its current resources are sufficient to fund operations for at least the next twelve months, as it continues to explore additional financing options to support its growth strategy.

MacroGenics’ MGC026 Study: A New Hope for Advanced Solid Tumors?

MacroGenics Inc. is conducting a Phase 1/1b clinical study titled ‘A Study of MGC026 in Participants With Advanced Solid Tumors.’ The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in patients with advanced solid tumors. This research is significant as it explores a potential new treatment option for patients with limited alternatives.

MacroGenics Appoints Eric Risser as New CEO

On August 13, 2025, MacroGenics announced the appointment of Eric Risser as President, Chief Executive Officer, and Director, succeeding Scott Koenig, who led the company for 24 years. Risser, previously the Chief Operating Officer, aims to focus on creating a capital-efficient biotechnology company that delivers novel therapies for cancer patients, reflecting a strategic shift in leadership and vision for the company’s future.

The most recent analyst rating on (MGNX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on MacroGenics stock, see the MGNX Stock Forecast page.

MacroGenics’ Prostate Cancer Study: A Potential Game-Changer?

Study Overview: MacroGenics Inc. is conducting a Phase 2 clinical study titled A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer. The study aims to assess whether adding lorigerlimab to the standard treatment of docetaxel and prednisone can delay disease progression in patients with metastatic castration-resistant prostate cancer (mCRPC). This study is significant as it explores potential improvements in treatment outcomes for this challenging condition.

MacroGenics’ Phase 2 Study: A Potential Game-Changer in Prostate Cancer Treatment?

Study Overview: MacroGenics Inc. is conducting a Phase 2 clinical study titled A Phase 2, Randomized, Open-Label, Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer. The study aims to evaluate whether the combination of lorigerlimab with docetaxel and prednisone can extend the time before disease progression in patients with metastatic castration-resistant prostate cancer (mCRPC). This research is significant as it explores potential improvements in treatment efficacy for a challenging cancer type.

MacroGenics’ Promising Study on Advanced Solid Tumors: Key Insights for Investors

MacroGenics Inc. is conducting a clinical study titled A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and preliminary antitumor activity of vobramitamab duocarmazine and lorigerlimab in patients with advanced solid tumors, including prostate cancer, melanoma, and others.